Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Phase 2TerminatedNCT00908024

Bristol-Myers Squibb54 enrolled

Overview

The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The study is also intended to collect first data on the effects of the combination of BMS-754807 with cetuximab on tumors of patients with colorectal cancer or squamous cell cancer of the head and neck for whom cetuximab-containing therapies have not been effective

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Cancer Head and Neck Cancer Neoplasm Metastasis

Interventions

BMS-754807DRUG

Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision

cetuximab (Erbitux®)DRUG

IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Inclusion Criteria: * ECOG status 0 - 1 * Dose escalation: Subjects with locally advanced or metastatic solid tumors who are eligible to receive cetuximab treatment and have archived tumor biopsy material available. Colorectal cancer subjects must be confirmed KRAS wild type * Dose expansion: CRC (KRAS-WT) and head \& neck cancer subjects only 1. must be able to provide 2 fresh tumor biopsy samples 2. must have failed one prior cetuximab-containing treatment Exclusion Criteria: * Symptomatic brain metastasis * Prior treatments with anti-EGFR (except cetuximab) or anti-IGF-1R agents, experimental or licensed * Any condition requiring chronic use of steroids * Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2 Diabetes Mellitus or prediabetic symptoms) * History of glucose intolerance * History of cetuximab infusion reactions * Women of child-bearing potential unwilling or unable to use acceptable contraception methods

Locations (5)

Nebraska Methodist Hospital

Omaha, Nebraska, United States

Duke University Medical Center

Durham, North Carolina, United States

University Of Wisconsin

Madison, Wisconsin, United States

Local Institution

Vancouver, British Columbia, Canada

Outcomes

Primary Outcomes

Maximum tolerated dose of BMS-754807 administered orally (daily schedule) in combination with cetuximab administered standard doses IV (weekly basis) will be determined by observation of dose limiting toxicities during the first 33 days of administration

Time frame: During and at the end of the first 33 days after the first dose of BMS-754807 is given

Secondary Outcomes

To assess anti-tumor activity as measured by objective responses

Time frame: every 8 weeks

To evaluate the safety and tolerability of the BMS-754807/cetuximab combination regimen

Time frame: Ongoing

To assess the effects of the BMS-754807/cetuximab combination regimen on glucose homeostasis

Time frame: Ongoing

Dose Expansion only: To identify biomarkers that are predictive of a response to BMS-754807/cetuximab combination therapy in advanced or metastatic CRC and SCCHN subjects with cetuximab resistance

Time frame: tumor biopsies before treatment and on day 33 +/- 3 of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.